Clinical trials
Gastroesophageal Junction (GEJ) Cancer clinical trials
Below are recruiting gastroesophageal junction (gej) cancer clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06902545Recruiting
Safety study of VYLOY for stomach or GEJ cancer in South Korea
This study monitors the safety of VYLOY (a cancer medicine) given to people in South Korea with stomach or gastroesophageal junction cancer. It helps doctors learn more about real-world side effects and how well patients do on treatment.
Goyang-si, Gyeonggi-doAges Any age - NCT05205343Recruiting
Compare minimally invasive and full stomach surgery for upper cancer
This study compares two minimally invasive ways to operate on the stomach area for cancers near the stomach and esophagus (GEJ). It looks at whether one surgical approach is better for long-term outcomes when the goal is cure.
Rochester, MinnesotaAges 18 years+ - NCT07546812RecruitingPhase 2
Testing Denikitug for advanced stomach and esophageal cancer
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Boston, MassachusettsAges 18 years+ - NCT07552402Recruiting
Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Shijiazhuang, HebeiAges 18–75 - NCT05651594RecruitingPhase 2
Propranolol with pembrolizumab and chemotherapy for esophageal cancer
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Buffalo, New YorkAges 18 years+ - NCT07139951Enrolling by invitationPhase 2
Heated Chemotherapy for Stomach Cancer at High Risk of Recurrence
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
Rochester, MinnesotaAges 18–80 - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
DoradoAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT07692204RecruitingPhase 2
Testing a new drug for advanced stomach cancer
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
ShanghaiAges 18 years+ - NCT04447352RecruitingPhase 3
HIPEC plus FLOT versus FLOT alone for gastric or GE junction cancer
This trial compares two treatment approaches after your stomach/GE junction cancer has been treated with chemotherapy before surgery: adding a special heated bath into the abdomen (HIPEC) plus continuing the usual surgery plan. It aims to see if adding HIPEC lowers cancer coming back and improves outcomes.
AachenAges 18–75 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05187182RecruitingPhase 1
Testing a new cancer drug with FOLFOX and immune therapy
This Phase 1 study tests CA-4948 given with standard chemotherapy (FOLFOX) and an immune therapy (an immune checkpoint inhibitor, similar to PD-1). It’s for people with advanced stomach or esophageal cancer that can’t be removed by surgery, to see how well the treatment works and whether it’s safe.
St Louis, MissouriAges 18 years+ - NCT05365581RecruitingPhase 1
Study drug for stomach and pancreatic cancers with lab-checked targets
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Orange, CaliforniaAges 18 years+ - NCT05439993RecruitingPhase 1/Phase 2
Tepotinib plus paclitaxel for MET-altered stomach cancer
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
Gyeonggi-doAges Any age - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT05687357RecruitingPhase 2
Tislelizumab plus chemoradiation before surgery for stomach cancer
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Wuhan, HubeiAges 18–75 - NCT05872295RecruitingPhase 1
Study drug for HER2-positive advanced cancers
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Newport Beach, CaliforniaAges 18 years+ - NCT05894824RecruitingPhase 1/Phase 2
T-DXd with ramucirumab for HER2-low stomach and GEJ cancer
This trial studies T-DXd given with ramucirumab to treat stomach (gastric) or stomach–esophagus junction (GEJ) cancer that has spread or is locally advanced and is “HER2-low.” It’s mainly to test safety and early effectiveness in people whose cancer continued after first-line treatment.
Seoul, SeoulAges 19 years+ - NCT06038578RecruitingPhase 2
TRK-950 with standard chemo for advanced stomach cancer
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
Duarte, CaliforniaAges 18 years+ - NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75
Hear when a new Gastroesophageal Junction (GEJ) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastroesophageal junction (gej) cancer?
- Yes. Clin2 currently lists 65 recruiting gastroesophageal junction (gej) cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastroesophageal junction (gej) cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastroesophageal junction (gej) cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Gastroesophageal-junction Cancer
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.